Menu

HomeConferencesCollectionsCalls for PapersMSF Research EthicsClinical Case ReportingAboutMy Saved Content
Logo

Science Portal

  • My Saved Content
  • Browse All
  • Conferences
  • Collections
  • Calls for Papers
  • MSF Research Ethics
  • Clinical Case Reporting
  • About
English
logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.prod.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.prod.produseast1
World Hepatitis Day 2023 | Collections | MSF Science Portal
World Hepatitis Day 2023

World Hepatitis Day 2023

Viral hepatitis is a major cause of disease and death globally. To mark World Hepatitis Day (July 28th) we present a selection of recent MSF research exploring how to effectively deploy powerful medical tools that could turn the tide on hepatitis C and E—but now reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.

For hepatitis C, where groundbreaking new antiviral drugs can cure nearly all patients, MSF is piloting simplified, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. Some programs focus on the complex needs of highly vulnerable, hard-to-reach populations, such as people co-infected with HIV or TB or who inject drugs.

Turning to prevention, an ongoing vaccination campaign against hepatitis E in an outbreak setting is showing early signs of short-term protection. Final results from this South Sudanese refugee camp, where poor sanitation and water quality regularly lead to outbreaks, should help plug a key evidence gap that—along with other barriers discussed in a commentary article—impedes widespread uptake of the vaccine.

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (8)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (8)
  • CSV
  • BibTeX
  • EndNote

See more collections

The endTB project

The endTB project

The endTB project aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. This collection contains the final and intermediate results of the studies, advocacy reports, and study presentations. For more information about the endTB project, visit https://endtb.org/.

Safe abortion care at MSF

Safe abortion care at MSF
MSF Science Portal

MSF Science Portal
View All Collections

Unsafe abortion is a major cause of maternal death, and the only one that is completely preventable. Yet over 30 million unsafe abortions occur each year, leading to at least 29,000 deaths and millions of serious complications—nearly all in low- and middle-income countries. MSF teams see these tragic consequences first-hand, treating thousands of patients every year with severe, potentially life-threatening effects from unsafe abortion.


To mark International Safe Abortion Awareness Day (28 September 2024), this Collection presents highlights of MSF’s work on safe abortion care (SAC) as a way to reduce maternal death and injury. By re-assessing and reshaping how our projects deliver SAC in fragile and conflict-affected settings, we have been able to significantly expand services in those contexts and across MSF projects globally. In parallel, we also conducted in-depth studies of abortion complications and their contributing factors in fragile settings, where a dearth of evidence limits understanding of women's needs in accessing comprehensive care. These findings are helping to identify gaps in service delivery and inform operational decision-making.

While Médecins Sans Frontières (MSF) is known mostly for providing direct medical aid to people affected by conflict, epidemics, disasters, or exclusion from health services, we also conduct research aimed at improving patient care and advocating for evidence-based policy and practices. To this end we conduct hundreds of research studies each year, publish extensively in peer-reviewed journals, and present our findings at scientific conferences around the world, including several annual MSF-organized events.


With the MSF Science Portal we introduce a new platform that aims to be a « one-stop shop » for content related to this work, so that users anywhere can easily find, browse, access, share and use the knowledge our research generates. Alongside frequent updates of new publications, conference materials, reports and featured content, we will continue to develop this site and to expand its range of content. To learn more about the Portal and what it offers, check out the short videos and slide presentation in this collection.

Conference Material
|
Abstract

Safety of hepatitis E vaccination in pregnancy following the first mass reactive vaccination campaign in Bentiu, South Sudan

Nesbitt RC
2023-06-08 • Epicentre Scientific Day Paris 2023
2023-06-08 • Epicentre Scientific Day Paris 2023
BACKGROUND
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against H...
Conference Material
|
Slide Presentation

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|
Research

Nurse-led initiation of hepatitis C care in rural Cambodia

O’Keefe D, Samley K, Bunreth V, Marquardt T, Bobi SE,  et al.
2023-04-01 • Bulletin of the World Health Organization
2023-04-01 • Bulletin of the World Health Organization
OBJECTIVE
To determine whether a nurse-led model of care for patients with hepatitis C virus (HCV) infections can provide safe and effective diagnosis and treatment in a resource-poo...
Journal Article
|
Research

Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5-year retrospective analysis of routine programmatic data

Loarec A, Gutierrez AG, Muvale G, Couto AM, Nguyen AP,  et al.
2023-03-30 • Health Science Reports
2023-03-30 • Health Science Reports
BACKGROUND AND AIMS
Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médeci...
Journal Article
|
Research

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa

Saayman E, Hechter V, Kayuni N, Sonderup MW
2023-03-04 • Harm Reduction Journal
2023-03-04 • Harm Reduction Journal

BACKGROUND

Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PW...

Journal Article
|
Research

Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study

Swe TM, Johnson DC, Mar HT, Thit P, Homan T,  et al.
2023-02-17 • Health Science Reports
2023-02-17 • Health Science Reports
BACKGROUND AND AIMS
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplificati...
Journal Article
|
Commentary

Hepatitis E vaccine—Illuminating the barriers to use

Lynch JA, Lim JK, Asaga PEP, Wartel TA, Marti M,  et al.
2023-01-05 • PLOS Neglected Tropical Diseases
2023-01-05 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...